Cancer Family
Neoplasm
CI-CAN-00000001Explore in graph →
Non-malignant22,971 active trials259 approved drugs4,031 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000001Explore in graph →
Clinical trials
105,884 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05215379 | Neoadjuvant Chemoradiation Therapy Combined With Immunotherapy for MSS Ultra-low Rectal Cancer | completed | Phase 2 / Phase 3 | 201 | Changhai HospitalOTHER | 1 | Jan 2, 2026 | clinicaltrials |
| NCT00980954 | Chemotherapy and Pelvic Radiation Therapy With or Without Additional Chemotherapy in Treating Patients With High-Risk Early-Stage Cervical Cancer After Radical Hysterectomy | completed | Phase 3 | 236 | Radiation Therapy Oncology GroupNETWORK | 4 | Dec 31, 2025 |
| clinicaltrials |
| NCT01809691 | S1216, Phase III ADT+TAK-700 vs. ADT+Bicalutamide for Metastatic Prostate Cancer(S1216) | completed | Phase 3 | 1,313 | SWOG Cancer Research NetworkNETWORK | 1 | Dec 31, 2025 | clinicaltrials |
| NCT04442048 | Immunization With IMM-101 vs Observation for Prevention of Respiratory and Severe COVID-19 Related Infections in Cancer Patients at Increased Risk of Exposure(COV-IMMUNO) | completed | Phase 3 | 195 | Canadian Cancer Trials GroupNETWORK | 1 | Dec 30, 2025 | clinicaltrials |
| NCT00133887 | TUMORAPA 1: Efficacy of Rapamycin in Secondary Prevention of Skin Cancers in Kidney Transplant Recipients | completed | Phase 3 | 77 | Hospices Civils de LyonOTHER | 1 | Dec 26, 2025 | clinicaltrials |
| NCT04148911 | A Study of Atezolizumab Plus Nab-Paclitaxel in the Treatment of Unresectable Locally Advanced or Metastatic PD-L1-Positive Triple-Negative Breast Cancer(EL1SSAR) | completed | Phase 3 | 184 | Hoffmann-La RocheINDUSTRY | 13 | Dec 26, 2025 | clinicaltrials |
| NCT04889118 | Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | completed | Phase 3 | 131 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT00757302 | Intraoperative Gamma Camera for Breast Cancer Surgery | completed | Phase 3 | 110 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT04471428 | Study of Atezolizumab in Combination With Cabozantinib Versus Docetaxel in Patients With Metastatic Non-Small Cell Lung Cancer Previously Treated With an Anti-PD-L1/PD-1 Antibody and Platinum-Containing Chemotherapy(CONTACT-01) | completed | Phase 3 | 366 | Hoffmann-La RocheINDUSTRY | 15 | Dec 22, 2025 | clinicaltrials |
| NCT00799188 | CERTICOEUR: A Secondary Prevention Study of Skin Cancers in Heart Transplant Patients. Everolimus Versus Calcineurin Inhibitors Multicenter Trial(CERTICOEUR) | completed | Phase 3 | 175 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT02314182 | GRECCAR 8: Primary Tumor Resection in Rectal Cancer With Unresectable Metastasis(GRECCAR8) | completed | Phase 3 | 5 | Hospices Civils de LyonOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT03180736 | Comparison of Pom and Dex in Subjects With RRMM Previously Treated With Len and a PI Dara/Pom/Dex vs Pom/Dex(EMN14) | completed | Phase 3 | 304 | Stichting European Myeloma NetworkNETWORK | 10 | Dec 19, 2025 | clinicaltrials |
| NCT00117286 | Extension Study Investigating the Long-Term Safety of Degarelix One-Month Depots in Patients With Prostate Cancer | completed | Phase 2 / Phase 3 | 57 | Ferring PharmaceuticalsINDUSTRY | 2 | Dec 18, 2025 | clinicaltrials |
| NCT03009981 | A Study of Androgen Annihilation in High-Risk Biochemically Relapsed Prostate Cancer | completed | Phase 3 | 504 | Alliance Foundation Trials, LLC.OTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03215706 | A Study of Nivolumab and Ipilimumab Combined With Chemotherapy Compared to Chemotherapy Alone in First Line NSCLC(CheckMate 9LA) | completed | Phase 3 | 719 | Bristol-Myers SquibbINDUSTRY | 19 | Dec 17, 2025 | clinicaltrials |
| NCT05114720 | Moxifloxacin in Adjuvant Treatment of Patients With Operable Breast Cancer | completed | Phase 3 | 559 | Sun Yat-sen UniversityOTHER | 1 | Dec 17, 2025 | clinicaltrials |
| NCT02881086 | Optimization of Therapy in Adult Patients With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma by Individualised, Targeted and Intensified Treatment | completed | Phase 3 | 1,023 | Goethe UniversityOTHER | 1 | Dec 16, 2025 | clinicaltrials |
| NCT02926196 | Adjuvant Treatment for High-risk Triple Negative Breast Cancer Patients With the Anti-PD-l1 Antibody Avelumab(A-Brave) | completed | Phase 3 | 474 | Istituto Oncologico Veneto IRCCSOTHER | 2 | Dec 12, 2025 | clinicaltrials |
| NCT04157985 | Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors | completed | Phase 3 | 161 | Dan ZandbergOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04063163 | A Phase III Study to Investigate Efficacy and Safety of HLX10 + Chemotherapy in Patients With ES-SCLC | completed | Phase 3 | 585 | Shanghai Henlius BiotechINDUSTRY | 5 | Dec 9, 2025 | clinicaltrials |
| NCT03013010 | PREACT Study: Locally Advanced Gastric Cancer, Chemoradiotherapy vs. Chemotherapy Followed by D2 Surgery and Adjuvant Chemotherapy(PREACT) | completed | Phase 3 | 204 | Shanghai Cancer Hospital, ChinaOTHER | 1 | Dec 8, 2025 | clinicaltrials |
| NCT03735121 | A Study to Investigate Atezolizumab Subcutaneous in Patients With Previously Treated Locally Advanced or Metastatic Non-Small Cell Lung Cancer | completed | Phase 3 | 438 | Hoffmann-La RocheINDUSTRY | 23 | Dec 5, 2025 | clinicaltrials |
| NCT02421939 | A Study of ASP2215 Versus Salvage Chemotherapy in Patients With Relapsed or Refractory Acute Myeloid Leukemia (AML) With FMS-like Tyrosine Kinase (FLT3) Mutation | completed | Phase 3 | 371 | Astellas Pharma Global Development, Inc.INDUSTRY | 14 | Dec 4, 2025 | clinicaltrials |
| NCT06007586 | Prevention and Treatment of CINV Caused by TC Regimen in Gynecological Malignant Tumor Patients | completed | Phase 3 | 143 | Sichuan Cancer Hospital and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT03808805 | Aprepitant Versus Hydroxyzine in Persistent Aquagenic Pruritus for Patients With Myeloproliferative Neoplasms(APHYPAP) | completed | Phase 3 | 63 | University Hospital, BrestOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04620369 | Rose Geranium in Sesame Oil Nasal Spray for the Improvement of Nasal Vestibulitis Symptoms in Cancer Patients Receiving Chemotherapy | completed | Phase 3 | 106 | Mayo ClinicOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT04865289 | Pembrolizumab (MK-3475) Plus Lenvatinib (E7080/MK-7902) Versus Chemotherapy for Endometrial Carcinoma (ENGOT-en9 / MK-7902-001) - China Extension Study(LEAP-001) | completed | Phase 3 | 130 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Dec 2, 2025 | clinicaltrials |
| NCT03223376 | A Phase III Study of Fruquintinib in Combination With Paclitaxel in Second Line Gastric Cancer(FRUTIGA)(FRUTIGA) | completed | Phase 3 | 703 | Hutchison Medipharma LimitedINDUSTRY | 1 | Dec 1, 2025 | clinicaltrials |
| NCT03391466 | Study of Effectiveness of Axicabtagene Ciloleucel Compared to Standard of Care Therapy in Patients With Relapsed/Refractory Diffuse Large B Cell Lymphoma(ZUMA-7) | completed | Phase 3 | 359 | Kite, A Gilead CompanyINDUSTRY | 14 | Dec 1, 2025 | clinicaltrials |
| NCT01358877 | A Study of Pertuzumab in Addition to Chemotherapy and Trastuzumab as Adjuvant Therapy in Participants With Human Epidermal Growth Receptor 2 (HER2)-Positive Primary Breast Cancer(APHINITY) | completed | Phase 3 | 4,804 | Hoffmann-La RocheINDUSTRY | 42 | Nov 28, 2025 | clinicaltrials |
| NCT05600309 | A Study of Coformulated Favezelimab/Pembrolizumab (MK-4280A) Versus Standard of Care in Subjects With Previously Treated Metastatic PD-L1 Positive Colorectal Cancer (MK-4280A-007)-China Extension Study | completed | Phase 3 | 94 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05445167 | A Clinical Study of KLH-2109 in Uterine Fibroids Patient With Menorrhagia and Pain | completed | Phase 3 | 89 | Kissei Pharmaceutical Co., Ltd.INDUSTRY | 1 | Nov 25, 2025 | clinicaltrials |
| NCT02918955 | Definitive Chemo-Radiotherapy for Regionally Advanced Head and Neck Cancer With or Without Up-front Neck Dissection(UPFRONT-NECK) | completed | Phase 3 | 65 | Insel Gruppe AG, University Hospital BernOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT02442375 | Uniform FDG-PET Guided Gradient Dose Prescription to Reduce Late Radiation Toxicity(UPGRADE-RT) | completed | Phase 3 | 300 | Radboud University Medical CenterOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02743494 | An Investigational Immuno-therapy Study of Nivolumab or Placebo in Participants With Resected Esophageal or Gastroesophageal Junction Cancer(CheckMate 577) | completed | Phase 3 | 794 | Bristol-Myers SquibbINDUSTRY | 31 | Nov 18, 2025 | clinicaltrials |
| NCT03079011 | PAlbociclib and Circulating Tumor DNA for ESR1 Mutation Detection(PADA-1) | completed | Phase 3 | 1,017 | UNICANCEROTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT02967289 | IRinotecan and Oxaliplatin for Colon Cancer in Adjuvant Setting(IROCAS) | completed | Phase 3 | 792 | UNICANCEROTHER | 2 | Nov 17, 2025 | clinicaltrials |
| NCT04338399 | The BURAN Study of Buparlisib in Patients With Recurrent or Metastatic HNSCC(BURAN) | completed | Phase 3 | 487 | Adlai Nortye Biopharma Co., Ltd.INDUSTRY | 17 | Nov 17, 2025 | clinicaltrials |
| NCT03371017 | A Study of the Efficacy and Safety of Atezolizumab Plus Chemotherapy for Patients With Early Relapsing Recurrent Triple-Negative Breast Cancer(IMpassion132) | completed | Phase 3 | 595 | Hoffmann-La RocheINDUSTRY | 28 | Nov 12, 2025 | clinicaltrials |
| NCT02242942 | Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia | completed | Phase 3 | 445 | Hoffmann-La RocheINDUSTRY | 21 | Nov 6, 2025 | clinicaltrials |
| NCT02831959 | Pivotal, Open-label, Randomized Study of Radiosurgery With or Without Tumor Treating Fields (TTFields) for 1-10 Brain Metastases From Non-small Cell Lung Cancer (NSCLC). | completed | Phase 3 | 298 | NovoCure GmbHINDUSTRY | 15 | Oct 31, 2025 | clinicaltrials |
| NCT02477826 | An Investigational Immuno-therapy Trial of Nivolumab, or Nivolumab Plus Ipilimumab, or Nivolumab Plus Platinum-doublet Chemotherapy, Compared to Platinum Doublet Chemotherapy in Patients With Stage IV Non-Small Cell Lung Cancer (NSCLC)(CheckMate 227) | completed | Phase 3 | 2,747 | Bristol-Myers SquibbINDUSTRY | 33 | Oct 30, 2025 | clinicaltrials |
| NCT03036488 | Study of Pembrolizumab (MK-3475) Plus Chemotherapy vs Placebo Plus Chemotherapy as Neoadjuvant Therapy and Pembrolizumab vs Placebo as Adjuvant Therapy in Participants With Triple Negative Breast Cancer (TNBC) (MK-3475-522/KEYNOTE-522) | completed | Phase 3 | 1,174 | Merck Sharp & Dohme LLCINDUSTRY | 21 | Oct 29, 2025 | clinicaltrials |
| NCT03136445 | TRial to EvaluAte Tranexamic Acid Therapy in Thrombocytopenia(TREATT) | completed | Phase 3 | 616 | NHS Blood and TransplantOTHER_GOV | 2 | Oct 28, 2025 | clinicaltrials |
| NCT02294461 | An Asian Study to Evaluate Efficacy and Safety of Oral Enzalutamide in Progressive Metastatic Prostate Cancer Participants | completed | Phase 3 | 395 | Astellas Pharma IncINDUSTRY | 4 | Oct 24, 2025 | clinicaltrials |
| NCT03269994 | Does Cefoxitin or Piperacillin-Tazobactam Prevent Postoperative Surgical Site Infections After Pancreatoduodenectomy? | completed | Phase 3 | 967 | Memorial Sloan Kettering Cancer CenterOTHER | 2 | Oct 21, 2025 | clinicaltrials |
| NCT02252172 | Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Participants With Previously Untreated Multiple Myeloma | completed | Phase 3 | 737 | Janssen Research & Development, LLCINDUSTRY | 13 | Oct 20, 2025 | clinicaltrials |
| NCT04838613 | Study of Diagnostic Performance of [18F]CTT1057 in BCR(GuidePath) | completed | Phase 3 | 190 | Novartis PharmaceuticalsINDUSTRY | 4 | Oct 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 2, 2026source: clinicaltrials